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Hereditary breast and ovarian cancer (HBOC) is an inherited cancer 
syndrome that is associated with mutations in the BRCA1 and BRCA2 genes. 
Carriers of BRCA mutations, both men and women, are at an increased risk for 
developing certain cancers. Carriers are most notably at an increased risk to 
develop breast and ovarian cancers; however an increased risk for prostate cancer, 
melanoma, and pancreatic cancers has also been associated with these mutations. In 
2009 the American Congress of Obstetricians and Gynecologists (ACOG) released a 
practice bulletin stating that evaluating a patient’s risk for HBOC should be a 
routine part of obstetric and gynecologic practice.  
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A survey was created and completed by 83 obstetricians and gynecologists in 
the greater Houston, TX area. The survey consisted of four sections designed to 
capture demographic information, attitudes towards HBOC and BRCA testing, 
utilization of BRCA testing, and the overall knowledge of respondents with regards 
to HBOC and BRCA testing. This study found that the majority of participants 
indicated that they felt that obstetricians and gynecologists should have the 
primary responsibility of identifying patients who may be at increased risk of 
carrying a BRCA mutation. Moreover, this study found that the majority of 
participants indicated that they felt comfortable or very comfortable in identifying 
patients at an increased risk of carrying a BRCA mutation.  However, only about a 
quarter of participants indicated that they order BRCA genetic testing one to two 
times per month or more.  Lastly, this study demonstrates that the overall 
knowledge of HBOC and BRCA testing among this population of obstetricians and 
gynecologists is poor.   
The results of this study stress the need for more education regarding HBOC, 
genetic testing, and strategies for identifying patients that may be at risk for having 
a mutation in a BRCA gene. Furthermore, it reiterates the importance of raising 
awareness to current practice guidelines and recommendations that can assist 
obstetricians and gynecologist to better identify and manage patients that may be at 
an increased risk of having HBOC. 
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BACKGROUND 
Introduction  
 Hereditary breast and ovarian cancer (HBOC) is an inherited cancer syndrome 
that is associated with mutations in the BRCA1 and BRCA2 genes [1,2]. Mutations in 
either BRCA1 or BRCA2 are inherited in an autosomal dominant manner, and these 
mutations cause carriers, both men and women, to be at an increased risk for 
developing certain cancers. Carriers are most notably at an increased risk to 
develop breast and ovarian cancers; however an increased risk for prostate cancer, 
melanoma, and pancreatic cancers have also been associated with these mutations 
[3,4].   
 
Prevalence  
Originally, it was estimated that 1/5000-1/10000 individuals in the general 
population carried a mutation in either the BRCA1 or BRCA2 gene [5]. However, 
with recent advancements in research and testing, the accepted prevalence of BRCA 
mutation carriers is now thought to be between to 1/400 and 1/800 individuals in 
the general population [6,7]. This number becomes even more significant in select 
populations, such as Ashkenazi Jewish individuals, where founder mutations in 
BRCA1 and BRCA2 have been identified. Three specific mutations have been 
identified in the Ashkenazi Jewish population and include the 185delAG and 
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5382insC mutations in the BRCA1 gene and the 6174delT mutation in the BRCA2 
gene [8]. The prevalence of a BRCA mutation in the Ashkenazi Jewish population is 
1/40 [9]. Other specific founder mutations have been described in individuals from 
Iceland, Norway, Finland, Sweden, France, the Netherlands, Italy, Mexico, and 
Pakistan [10].  
BRCA1  
The BRCA1 gene, located on chromosome 17q21, was first mapped in 1990 
[11,12]. The BRCA1 gene consists of 22 coding exons, spanning 80 kb of DNA [13]. 
Since that time it was thought to have many regulatory functions within the cell. 
One such function of the BRCA1 gene is to act as a negative regulator of tumor 
growth or as a tumor suppressor gene [1].  Moreover, the BRCA1 gene is thought to 
play a part in the repair and regulation of cell-cycle checkpoints in response to 
DNA lesions with indications of damage [14]. The exact molecular mechanisms and 
role of the BRCA1 gene are still under investigation today. To date, there have been 
more than 1600 mutations identified in the BRCA1 gene, the majority of which are 
frameshift mutations resulting in non-functional protein products [15]. 
 
BRCA2 
The BRCA2 gene, located on chromosome 13q12-q13, was identified shortly 
after the BRCA1 gene in 1994 [2]. This gene consists of 26 coding exons and spans 70 
3 
 
kb of DNA [13]. Like BRCA1, the BRCA2 gene is a tumor suppressor gene and its 
primary role is to maintain genomic integrity in DNA.  Studies have indicated that 
cells with a non-functional BRCA2 gene have been shown to be hypersensitive to 
ionizing radiation resulting in permanent DNA damage [16,17]. To date, there have 
been approximately 1800 mutations identified in the BRCA2 gene, which include 
frameshift deletions, insertions, and nonsense mutations [15]. As both BRCA genes 
act as tumor suppressor genes, individuals identified with a mutation in either their 
BRCA1 or BRCA2 gene are at an increased risk to develop breast, ovarian, and other 
associated cancers.  
 
Breast and Ovarian Cancer Risk 
In the general population, a woman has an approximate 12% risk of 
developing breast cancer and a 1.4% risk of developing ovarian cancer during her 
lifetime [18]. These risk estimates greatly increase if a mutation in either the BRCA1 
or BRCA2 genes is identified. Hereditary forms of both breast and ovarian cancer 
make up about 5-10% of all breast and ovarian cancers seen in the population [19]. 
Both the BRCA1 and BRCA2 genes have variable penetrance. That is to say, a 
mutation in BRCA1 or BRCA2 will significantly increase the likelihood to 
developing breast and ovarian cancer; however, all carriers do not develop cancer 
during their lifetime. Differences in penetrance can be seen between individuals 
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with BRCA1 or BRCA2 mutations and even between family members who carry the 
same identified mutation [20,21]. While generally referenced as a pair, both the 
BRCA1 and BRCA2 genes carry their own risk estimates with regards to developing 
breast and ovarian cancer. Several studies have examined the risk for developing 
breast and ovarian cancer in both the BRCA1 and BRCA2 genes individually. In 
2003, a meta-analysis of 22 studies looking at over 8,000 index cases found that 
individuals that carried a BRCA1 mutation had a 65% risk of developing breast 
cancer and a 39% risk of developing ovarian cancer by the age of 70 [22]. Analysis of 
this same study population also indicated that individuals that carried a BRCA2 
mutation had a 45% risk of developing breast cancer and an 11% risk of developing 
ovarian cancer before the age of seventy [22]. Following this analysis, in 2006, a 
separate group again tried to quantify the breast and ovarian cancer risks associated 
with BRCA1 and BRCA2 through population based studies. The first study looked 
at risks before the age of 80 years and found that individuals that carried a BRCA1 
mutation had a 90% risk of developing breast cancer and 24% risk of developing 
ovarian cancer [7]. The same group found that individuals with a mutation in the 
BRCA2 gene had a 41% risk to develop breast cancer and an 8.4% risk for 
developing ovarian cancer [7]. These two studies represent the variability seen in 
the literature with regards to associated risk. Based on the most up to date 
surveillance epidemiology and end results (SEER) cancer statistics, women that 
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carry a BRCA1 or BRCA2 mutation have a 60% lifetime risk to develop breast cancer 
and a 15-40% risk to develop ovarian cancer [18].  
Other studies have looked particularly at the risk to develop a second 
primary breast cancer in the same (ipsilateral) or opposite breast (contralateral).  
Most studies have found that younger age at the primary diagnosis is strongly 
correlated to increased risk for developing a contralateral breast cancer [23]. A 
woman without a BRCA mutation has a lifetime risk of 10% to develop 
contralateral breast cancer. For individuals with a mutation in either the BRCA1 or 
the BRCA2 gene this risk is increased to 13-30% [24,25]. One population based 
study, looking at women with a breast cancer detected before the age of 55 years, 
found that individuals with a BRCA1 mutation had a 4.5 fold increased risk while 
those that carried a mutation in the BRCA2 gene had a 3.4 fold increased risk for 
developing contralateral breast cancer [24]. In 2011, a UK cancer research team 
confirmed these results. They found that age of the primary breast cancer did in 
fact influence the risk estimates for developing contralateral breast cancer. 
Moreover, they quantified their findings showing that individuals with a BRCA1 
mutation had an approximate 36% risk estimate for developing contralateral breast 
cancer within 15 years from the primary diagnosis. Those with BRCA2 mutations 
were found to have 28.5% risk estimate for the same period [26]. Studies have 
shown however, that the risk for recurrence of breast cancer after surgery in 
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known BRCA carriers is not at an increased risk as compared to the general 
population [27]. Risk assessments for breast (both ipsilateral and contralateral) and 
ovarian cancers are constantly being investigated and updated, as more is 
understood.  
 
Other Associated Cancers  
The association between mutations in the BRCA genes and breast and 
ovarian cancer has been well established in the literature over the past twenty 
years. However, breast and ovarian cancers are not the only cancers associated with 
the BRCA1 and BRCA2 genes. Fallopian tube carcinoma, rare in the general 
population, has been associated with both BRCA1 and BRCA2 mutations [18,28,29]. 
For individuals with a known BRCA mutation the risk for fallopian tube carcinoma 
increases to 0.6%, about 120-fold increase compared to the general population [30]. 
Studies have also found up to an 11% lifetime risk for BRCA carriers to develop 
primary papillary serous carcinoma of the peritoneum, as compared to the general 
population risk of 0.07-0.24%.  
Individuals with BRCA2 mutations also have an increased risk of developing 
pancreatic cancer, male breast cancer, and prostate cancer. While the general 
population risk of male breast cancer is less than 1%, the National Cancer Institute 
(NCI) evaluated 97 males with breast cancer and found that those with a BRCA2 
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mutation had a 6.8% risk to develop breast cancer and men with a BRCA1 mutation 
had a 1.2% risk for breast cancer [32,33]. In the general population a man has about 
a 16% chance of developing prostate cancer in his lifetime [34]. Men with BRCA2 
mutations have a 4.6 fold risk over the general population of developing prostate 
cancer [4]. Similarly, there is a slightly increased 1.07 fold risk for individuals with a 
BRCA1 mutation to develop prostate cancer before the age of 70 years [35]. BRCA2 
mutations have also been shown to increase the risk for pancreatic cancer. One 
study found that individuals with a BRCA2 mutation have a 7.3% risk to develop 
pancreatic cancer in comparison to the 1.45% lifetime risk in the general population 
[18,36].  
Other cancers such as gallbladder, bile duct, and melanoma have also been 
associated with BRCA2 mutations [4]. In the general population the lifetime risks 
for developing both gallbladder and bile duct cancers are less than one percent 
while the lifetime risk to develop melanoma is 2% [18]. For BRCA2 mutation 
carriers the relative risk of developing gallbladder and bile duct cancers becomes 
4.97, while the relative risk for developing melanoma is 2.58 [4]. Identifying 
individuals that carry mutations in BRCA1 and BRCA2 is clinically important in 
order to provide accurate cancer risk assessment and in order to create personalized 
management plans.  
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Molecular Testing  
Testing for mutations in BRCA1 and BRCA2 became commercially available 
in the United States in 1996 through Myriad Genetics laboratory. While Myriad 
Genetics is currently the only laboratory offering full sequencing of the BRCA 
genes, other laboratories are offering both multisite and single site testing. Through 
Myriad, there are currently four testing types offered with regards to the BRCA 
genes [37]. These four mutational analyses are comprehensive analysis, single site 
analysis, multisite analysis, and rearrangement analysis. Comprehensive 
BRACAnalysis®, includes full sequencing of the BRCA1 and BRCA2 genes as well 
as analysis of five specific large rearrangements in the BRCA1 gene. BRCA1 full 
sequencing includes both forward and reverse directions of 22 coding exons and 
about 750 base pairs in the adjacent non-coding introns. Similarly, BRCA2 full 
sequencing includes both forward and reverse directions of 26 coding exons and 
approximately 900 base pairs in the adjacent non-coding introns. The five specific 
large rearrangements of BRCA1 included in comprehensive BRACAnalysis® 
include founder mutations found in individuals of Dutch and European ancestry 
[38]. Single site BRACAnalysis® is for individuals where a known familial 
deleterious mutation has been identified. This testing type evaluates an individual 
for a specific mutation that has previously been identified in their family. Multisite 
BRACAnalysis® is designed to look for the three founder mutations that have been 
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identified in the Ashkenazi Jewish population. Ashkenazi Jewish individuals have 
been found to have a 1/40 risk to be a carrier of a BRCA mutation [39]. One study 
evaluating a group of unselected Ashkenazi Jewish patients with breast cancer 
found that 12% had a mutation in one of these three founder mutation sites [40]. 
Similarly another study identified that 35% of unselected Ashkenazi Jewish patients 
with ovarian cancer carried one of the three founder mutations [41]. If a woman of 
Ashkenazi Jewish decent were to carry a BRCA mutation, 90% of the time it would 
be one of these three founder mutations. Therefore, recommendations for multisite 
testing for individuals of Ashkenazi Jewish ancestry regardless of a known familial 
mutation is indicated because of the high incidence in this population. Finally, 
BRACAnalysis® Rearrangement testing (BART) evaluates all coding exons of both 
the BRCA1 and BRCA2 genes for deletions and duplications [37]. Less than 2% of 
individuals with a strong family history suggestive of carrying a BRCA mutation 
with no deleterious mutation identified via comprehensive testing will have a 
positive BART testing result [42].  While BART testing is typically not covered by 
most insurance plans, utilization of this testing may be beneficial in individuals 
with previously negative comprehensive BRACAnalysis®. For patients evaluated 
for having a high risk of BRCA mutation and ROA October 2011 
 
Testing Results  
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There are three types of BRCA test results: positive, negative, and variant of 
uncertain significance (VUS). Individuals undergoing comprehensive 
BRACAnalysis® may receive one of the three aforementioned results. A negative 
test would indicate that no mutation was present or that a known non-deleterious 
change, which is found in the general population, was present and classified as a 
“favor polymorphism”.  A positive test result indicates a mutation was found and 
may be classified as a deleterious mutation or suspected deleterious depending on 
the level of clinical certainty backed by literature. This would indicate that the 
patient would benefit from added screening. Finally a VUS would indicate that a 
mutation was found but the exact nature of the mutation (deleterious or not) is still 
not known at this time. A VUS will continue to be studied by Myriad in an attempt 
to reclassify it as deleterious or a favor polymorphism. For single site 
BRACAnalysis®, multisite BRACAnalysis®, and BRACAnalysis® Rearrangement 
testing (BART) the possible results are either negative or positive.  
 
Identifying at risk individuals 
Many professional guidelines have been implemented in regards to 
identifying individuals who may be at increased risk of having a mutation in either 
BRCA1 or BRCA2 gene. The American Congress of Medical Genetics (1999), The 
American Society of Clinical Oncology (2003), The American Congress of Obstetrics 
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and Gynecology (2009), and the United States Preventive Services Task Force (2005) 
have all published guidelines regarding the identification of patients at a high risk 
to carry at BRCA mutation.  The National Comprehensive Cancer Network 
developed a set of clinical practice guidelines for identifying individuals at 
increased risks to have a mutation in either of the BRCA genes [57]. Those 
individuals identified may benefit from genetic testing and increased surveillance. 
Criteria for further risk evaluation, according to the NCCN guidelines, include 
individuals with one or more of the following:  
 For those individuals with cancer:  
1. Early onset of breast cancer (Clinically using age <50 years 
old)  
2. Triple negative breast cancer (estrogen receptor negative, 
progesterone receptor negative, and Human Epidermal 
Growth Factor Receptor 2 negative) 
3. Two breast cancer primaries in an individual 
4. Breast cancer at any age, with  
i. 1 close relative with breast cancer ≤ 50 years old 
ii. 1 close relative with epithelial ovarian/fallopian 
tube/primary peritoneal cancer at any age 
iii. 2 close relatives with breast cancer and/or 
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pancreatic cancer 
5. A combination of breast cancer with one or more of the 
following: thyroid cancer, sarcoma, adrenocortical carcinoma, 
endometrial cancer, pancreatic cancer, brain tumors, diffuse 
gastric cancer, dermatologic manifestations, or 
leukemia/lymphoma on the same side of family 
6.  Ovarian/fallopian tube/primary peritoneal cancer  
7.  Male breast cancer 
Unaffected individuals, with a family history of one or more of the 
following:  
1.  ≥ 2 breast primaries from the same side of family (maternal or 
paternal)  
2.  ≥ 1 ovarian primary from the same side of family (maternal 
or paternal)  
3.  A combination of breast cancer with one or more of the 
following: thyroid cancer, sarcoma, adrenocortical carcinoma, 
endometrial cancer, pancreatic cancer, brain tumors, diffuse 
gastric cancer, dermatologic manifestations, or 
leukemia/lymphoma on the same side of family  
4.  A known mutation in a breast cancer susceptibility gene  
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5.  From a population at risk (Ex. Ashkenazi Jewish ancestry)  
6.  Male breast cancer [57] 
Following the clinical availability of testing the U.S. Preventive Services Task Force 
(USPSTF) released a statement recommending that “women whose family history is 
associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 
genes be referred for genetic counseling and evaluation for BRCA testing” [58].  
 
Screening and Management  
Ordering BRCA testing and accurately interpreting the results is an 
important aspect to assist in formulating appropriate screening, risk reduction 
options, and medical management plans.  Clinical management recommendations 
have been published, by the National Comprehensive Cancer Network (NCCN), for 
individuals identified with a mutation in either of the BRCA genes. These 
recommendations include both increased and more frequent screening as well as 
prophylactic surgical options. The NCCN breast guidelines indicate monthly self 
breast examination beginning at 18 years old, semiannual clinical breast 
examinations beginning by age 25 years and annual mammograms and breast MRI 
screening at age 25 years or 10 years before the earliest age of onset in the 
individuals family [43,44]. Surgical options such as prophylactic bilateral 
mastectomy in individuals with BRCA mutations has been shown to reduce breast 
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cancer risk by up to 90% [45,46]. While screening guidelines for breast cancer risks 
have been established, ovarian cancer screening has been shown to be ineffective 
[47]. Transvaginal ultrasound and CA-125 levels every six months starting at 35 
years old or 5-10 years before the earliest age of onset in the individuals family is 
still the recommendation despite its lack of clinical utility [48]. Prophylactic bilateral 
salpingho-oophorectomy (BSO), once a woman has completed childbearing, is the 
most effective risk reduction strategy for ovarian cancer for individuals with a 
BRCA mutation [49]. Studies have shown that a prophylactic BSO reduces a 
woman’s risk of developing ovarian, peritoneal, and fallopian tube cancer by up to 
90%. Furthermore, prophylactic BSO reduces the risk of breast cancer by almost 
50% by eliminating hormone production that may contribute to development of 
cancer [49,50,51].  
A recent study showed that with no intervention the survival rate of BRCA 
carriers was between 53-71%. They also found that prophylactic oophorectomy by 
age 40 paired with either screening (MRI and mammography) or prophylactic 
mastectomy at age 40 increased survival by 24% for BRCA1 carriers and by 11% for 
BRCA2 carriers [52].  
 Chemoprevention, the use of agents to delay or reduce the risk of cancer or 
recurrence, is another management tool that has been used for risk reduction in 
individuals with BRCA mutations. Studies have reported that individuals with a 
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BRCA2 mutation may have up to a 62% reduced risk for breast cancer following a 
five-year tamoxifen course [53]. Individuals with BRCA1 mutations generally have 
ER/PR negative tumors and would therefore not benefit from chemoprevention. 
Alternatively, aromatase inhibitors, anti-estrogenic agents are also being 
investigated to determine the effects despite a woman’s estrogen receptor status. 
However, studies have reported that aromatase inhibitors may have associated 
risks such as hot flashes and increased incidence in bone fractures. The same study 
found that these aromatase inhibitors also reduce the risk of developing 
contralateral breast cancer [54]. Similarly oral contraceptive use has been associated 
with risk reduction for ovarian cancer in both BRCA1 and BRCA2 carriers. Small 
studies have shown that ovarian cancer risks in BRCA1 mutation carriers may be 
reduced by up to 50% with the use of an oral contraceptive. Similarly, ovarian 
cancer risks for BRCA2 carriers were shown to be reduced by up to 60% in this 
study population [55,56]. Through the understanding of the inheritance of the 
BRCA mutations, associated cancer risks, different testing options, and screening 
and management guidelines, one can begin to appreciate the importance of 
adequately individuals at risk of carrying BRCA mutations.  
 
In 2009, the American Congress of Obstetricians and Gynecologists (ACOG) and 
the Society of Gynecologic Oncologists (SGO) partnered to a release a practice 
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bulletin regarding clinical management guidelines for Obstetricians and 
Gynecologists with regards to HBOC. This bulletin, based off the 2008 version of 
the NCCN guidelines, first outlined how to identify individuals who should be 
offered a hereditary risk assessment.  The bulletin states that “evaluating a patient’s 
risk for hereditary breast and ovarian cancer syndrome should be a routine part of 
obstetric and gynecologic practice” [59].   
The ACOG Practice bulletin also discusses the best testing strategies for 
individuals at risk of carrying a BRCA mutation. They recommend that the when 
possible, genetic testing should begin with the “affected individual”. For this, full 
sequencing of the BRCA1 and BRCA2 genes is advised. Once a specific mutation is 
identified or if the specific mutation is known in the family then single-site testing is 
recommended. Furthermore, ACOG states that for specific populations where 
founder mutations are known (Ashkenazi Jewish, French Canadian, Icelandic, 
Netherlandic, and Swedish) common mutation testing versus full sequencing 
should be offered [59]. While the aforementioned guidelines are representative of 
the general consensus with regards to identifying at risk individuals, the question 
still remains as to who should be identifying these individuals.  
 
Previous Studies   
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Several studies have looked at the utilization of BRCA testing among 
physicians in the United States and abroad [60 ,62]. In a study of 1500 primary care 
physicians, 87% of respondents were aware of the availability of BRCA testing 
while only 25% reported to having ordered it in the past year. Furthermore, 
obstetricians and gynecologist, which made 16.7% of the surveyed population, were 
in fact the most likely of all physician specialties to order the BRCA testing as 
compared to other specialties [62].  Another study, which surveyed non-academic 
physicians who have ordered BRCA testing, found that a third of obstetricians and 
gynecologists counsel the patient without the assistance of genetic counselor [60]. 
Other studies have specifically focused on the knowledge and attitudes of 
gynecologists with regards to HBOC. In a study of 172 gynecologists in Germany, 
62% indicated that they would feel comfortable performing basic genetic counseling 
for a high risk patient but a majority, 94%, indicated the desire for more information 
on BRCA genetics [63]. Another study in the United States specifically looking at 
obstetricians and/or gynecologists residents and their knowledge of both HBOC 
and Lynch Syndrome, a hereditary condition caused by a mutations in the 
mismatch repair genes which increase the risks for colon and endometrial cancers, 
elucidated some areas of deficiency in knowledge with regards to how HBOC is 
inherited in families and what other cancer risks are associated with mutations in 
the BRCA1 and BRCA2 genes. Of 157 study participants, 51% incorrectly indicated 
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that colon cancer was associated with HBOC and only 62% correctly identified that 
a mutation could be inherited from paternal relatives. In one recent study, a group 
of 1,878 physicians from across the United States were surveyed and asked to 
identify individuals who should be referred for genetic testing and counseling 
based on the information provided in a vignette. Of those physicians that 
participated 18.1% identified themselves as obstetrician and/or gynecologists. This 
study found that among obstetricians and/or gynecologists only 57.3% were able to 
accurately identify a woman at a high risk for carrying a BRCA mutation [64].  
 
Significance of this study  
Hereditary breast and ovarian cancer syndrome is a well-defined and 
studied genetic condition. With the availability and documented benefits of cancer 
screening, early assessment of cancer risks and evaluation for hereditary cancer 
syndromes such as HBOC, it is important for implementing personalized screening 
and prevention guidelines for those found to have a BRCA mutation. These early 
interventions can ultimately reduce morbidity and mortality for both breast and 
ovarian cancer patients and can also assist in identifying other family members who 
may be at risk and could benefit from such information. While many women do not 
follow up with a primary care physician on a regular basis, some studies have 
shown an increase in the number of visits to their obstetricians and/or gynecologists 
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[65]. Therefore, obstetricians and/or gynecologists are in a position to identity 
patients who may benefit from BRCA testing. This study is designed to assess 
knowledge of HBOC and BRCA testing, attitude towards BRCA testing, and 
utilization of BRCA testing among obstetricians and/or gynecologists in the greater 
Houston area. With the information attained from this study, we hope to be able to 
begin to address areas where educational modules and clinical protocols may 
benefit patient care.  
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MATERIALS AND METHODS 
Study Design 
This study was conducted via questionnaire to determine the current knowledge, 
attitudes, and utilization of the Houston area obstetricians and/or gynecologists 
(Ob/Gyns) with regards to HBOC and BRCA testing. Specifically the aims of this 
study were to:  
1. Determine the knowledge of Ob/Gyns with regards to hereditary breast and 
ovarian cancer syndrome and BRCA testing.  
2. Assess how Ob/Gyns are utilizing BRCA testing. 
3. Determine what Ob/Gyns feel their role is with regards to BRCA testing.  
 
Database 
All the data obtained from the surveys was entered into a Microsoft Excel 
2010 spreadsheet. Each survey was assigned a unique identification number to 
ensure that the responses were anonymous.  All of the information was then coded 
in order to be entered into the statistical software package for higher-level analysis.  
An overall knowledge score was calculated for each participant that answered the 
knowledge based questions and this information was also used for multivariate 
analysis.  
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Study Approval 
The survey was approved by the Institutional Review Board at the 
University of Texas Health Science Center at Houston Graduate School of 
Biomedical Sciences (IRB# HSC-GSBS-11-0328). Additionally, a separate IRB 
approval was obtained from Woman’s Hospital of Texas (264839-1); which was also 
accepted at Kelsey-Seybold Clinic for survey distribution. Approval to begin survey 
collection was received by the Memorial Hermann Clinical Innovation & Research 
Institute in order to administer the surveys at the affiliated Memorial Hermann 
Hospital System’s institutions. Two institutions, Methodist Hospital and St. 
Joseph’s Hospital, accepted the aforementioned UT IRB for survey distribution.  
 
Study Population 
The study was distributed to 268 physicians across institutions which 
included: Memorial Hermann Texas Medical Center, Memorial Hermann Katy, 
Memorial Hermann Memorial City, Memorial Hermann Southwest, Woman’s 
Hospital, Kelsey-Seybold Clinic, Methodist Hospital Texas Medical Center, and St. 
Joseph’s Hospital. The inclusion criteria for this study was board certified or board 
eligible Ob/Gyns in the Houston area; which excluded all other physicians 
practicing in other specialties and Ob/Gyns still in residency.  The survey was only 
available in English and there was no opportunity for translation.  
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Survey/ Questionnaire 
A questionnaire (Appendix A) was created in order to assess a sample of 
Ob/Gyns in the greater Houston area. A review of the literature did not identify a 
validated questionnaire specifically evaluating Ob/Gyn’s knowledge, attitudes, 
or utilization of BRCA testing, therefore, an instrument was created.  The survey 
was revised by committee members through several phases to determine whether it 
was clearly worded and appropriately structured to gather the desired 
information.  Experts within the fields relevant to the questionnaire reviewed the 
survey in order to assess content and validity.  
A cover letter explaining the nature of the survey and serving as the consent 
document was included with each survey (See Appendix B). Participation in the 
survey served as consent.  
The questionnaire consisted of 40 questions and took about 15 minutes to 
complete. The questionnaire was divided into four main sections: (1) demographics, 
(2) attitude toward BRCA testing, (3) utilization of BRCA testing and (4) knowledge 
of BRCA testing. 
1.      Demographics: This section consisted of seven questions to gather gender, 
since the completing their residency, area of practice, practice setting, and 
number of patients typically seen per week. Questions in this section were 
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multiple choice and free response where applicable.  
2.      Attitudes toward BRCA testing: This section consisted of 5 questions 
regarding the overall comfort of identifying patients at risk of carrying a BRCA 
mutation, assessing participants’ views on whether identifying at risk patients 
was  on of their practice responsibilities, and determining barriers which could 
potentially prevent participants from ordering testing. Questions in this section 
were yes/no questions, multiple choice (some limited to one response while 
others were open to several responses), a five point likert scale to assess 
comfort (very uncomfortable, uncomfortable, uncertain, comfortable, and very 
comfortable), and free response where applicable.  
3.  Utilization of BRCA testing: This section consisted of seven questions designed 
to assess how often participants identified, initiated a conversation, ordered 
testing, or received questions related to hereditary breast and ovarian cancer 
and BRCA testing. Furthermore, this section served to gather information 
about participants’ referral patterns once an individual with a suspected BRCA 
mutation was identified. Answers in this section were gathered via a five point 
likert scale to assess how often each of the aforementioned scenarios arose. The 
likert scale assessed the average number of times per month each scenario 
arose with the following choices: never, rarely (<1 time/mo), sometimes (1-2 
times/month), often (3-4 times/month), and on a regular basis (>= 5 times/mo). 
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A multiple choice question was used to assess the participants’ referral 
patterns. 
4.  Knowledge of BRCA testing: This section consisted of twenty questions to 
assess the overall knowledge of each participant with regards to hereditary 
breast and ovarian cancer and BRCA testing. The questions in this section were 
yes/no choices with simple example patients to determine if the survey 
participant could correctly identify those at risk of having a BRCA mutation. 
Similarly, yes/no questions were used to determine knowledge of cancers 
associated with hereditary breast and ovarian cancer syndrome. Finally a series 
of multiple choice questions were used to assess the knowledge about the 
lifetime risks associated with hereditary breast and ovarian cancer syndrome 
and the type of testing that would be appropriate given a particular patient’s 
personal and family background.  
At the conclusion of the survey, there was a free response box designed for any 
comments regarding the survey or hereditary breast and ovarian cancer and BRCA 
testing in general.  
  
Survey/ Data Collection 
Two different methods of distribution were used in order to attempt to 
maximize the response rate. The first method was an online survey, with direct 
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contact information gathered from the respective hospital system email databases. 
A direct link to the survey, embedded in the body of the message, was sent out to 
all obtained email addresses. A follow up reminder email was sent out to all 
individuals for participation about one week after the initial distribution. The 
electronic version of the survey was created in such a way that individuals that 
participated in this format were allowed to skip over questions, but could not go 
back to change answers once the question had been submitted or skipped. IP 
addresses were tracked so that the survey could theoretically only be submitted 
once from a given computer. While individuals could theoretically use different 
computers to submit several responses, this would be highly unlikely. 
The second distribution method was via a hard copy of the survey with in 
person contact. This contact was made through the attendance of various monthly 
hospital meetings. Individuals that had previously completed the online version of 
the survey were asked not to take part at these visits, but there was no way to 
ensure that an individual did not complete both formats of the survey.  
Both hard copy and digital delivery methods were distributed between 
October 2011 and February 2012.  The institutions, in which one or both methods of 
delivery were utilized, included: Memorial Hermann Texas Medical Center (both 
online and in person distribution), Memorial Hermann Katy (in person 
distribution), Memorial Hermann Memorial City (both online and in person 
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distribution), Memorial Hermann Southwest (in person distribution), Woman’s 
Hospital (online and in person distribution), Kelsey-Seybold Clinic (online 
distribution), Methodist Hospital Texas Medical Center (online distribution), and St. 
Joseph’s Hospital (in person distribution).  
 
Statistical Analysis  
Both univariate and multivariate analyses were performed on all applicable 
variables using the statistical software package STATA (v. 11, College Station, TX). 
Descriptive charts and graphs were created using Microsoft Excel.  A comparison 
between groups was performed using contingency test (χ2 or Fisher exact tests), 
Mann-Whitney sign-rank or Kruskal-Wallis tests where appropriate.  Comparisons 
between paired groups were performed using Wilcoxon signed ranks test.  Linear 
and logistic regression models were used to assess any linear trends over a series of 
ordinal categories. Spearman’s correlation tests were utilized to assess the degree of 
correlation between two continuous variables.  Tests were considered statistically 
significant at p<0.05.
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RESULTS 
Survey Response 
The total number of physicians present at meetings and/or providing an 
email address for access for survey distribution was 232. Of the surveys distributed 
online, 18 (6.7%) were invalid emails and were returned immediately. There were 
ninety-two surveys that were returned as completed. Fifty nine of these were hard 
copies of the survey distributed at various departmental meeting. The rest, thirty 
three, were online versions of the survey distributed through the online Survey 
Monkey database. Of the thirty three surveys completed online, two were opened 
online but no questions were attempted. An additional seven surveys (2.6%) were 
excluded.  Of these seven, one was filled in by an RN, four were filled by physicians 
in residency, one was filled by a  visiting foreign medical physician, and one 
participant only filled out the demographics section leaving the rest of the survey 
blank. Of the 92 surveys returned, 83 were used in statistical analysis, which 
resulted in a (30.97%) response rate overall. In both formats of the survey 
respondents were selective in which questions they answered, which resulted in 
varying numbers of total responses for some questions.  
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Part I: Demographics 
Fifty three percent (n=44) of respondents were female, and forty seven 
percent (n=39) were male (Figure 1).  
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Of the eighty three participants, seventy six (92%) were board certified in 
obstetrics and gynecology, while the remaining seven (8%) were not. The 
participants were asked to indicate the years since the completion of their primary 
residency. The average years reported was 17.89 years with a range from 0-47 years. 
This was consistent with the median of the group, which was found to be eighteen 
years.  
 
30 
 
 
 
 
 
 
 
 
Seventy four (89.2%) participants indicated that they were not boarded in 
any other specialty, while nine (10.8%) indicated that they were. Of those, three 
(33.3%) were board certified in gynecologic oncology only, one (11.1%) was board 
certified in obstetrics only, two (22.2%) were boarded in gynecologic oncology, one 
(11.1%) was boarded in maternal fetal medicine, one (11.1%) was boarded in 
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reproductive endocrinology, and one chose no to indicate an additional sub-
specialty.   
 
 
 
 
 
 
Sixty nine (83%) participants identified their primary practice area as general 
obstetrics and/or gynecology, four (5%) were gynecology only, three (4%) as 
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gynecologic oncology, two (2%) as maternal fetal medicine, two (2%) as 
reproductive endocrinology, and three (4%) as urogynecology.  
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 The majority of participants, fifty six (67.5%), reported that they work in a 
private practice setting. Those that indicated private practice were then asked to 
indicate the average number of Ob/Gyns in their group. The average number of 
Ob/Gyns reported was 9.36 (SD 10.59). There were twenty seven (32.5%) 
participants who reported to work in an academic institution.  
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The respondents were asked to identify the number of patients they see in 
the outpatient setting during an average week. They were given five ranges and 
about half (46%) stated that they see between 51-100 patients per week. A quarter of 
respondents reported to see between 101-150 patients per week, while 19% stated 
they saw less than 50 per week. Only 6% and 4% of respondents reported to seeing 
151-200 and greater than 200 patients per week, respectively.  
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Part II: Attitude toward HBOC and BRCA testing  
The majority (57%) of respondents felt comfortable in identifying patients 
who are at an increased risk of carrying a BRCA mutation. An additional 20% of 
respondents indicated that they felt very comfortable with this task. The remaining 
10%, 4%, and 8% of respondents were very uncomfortable, uncomfortable, or 
uncertain, respectively, with regards to identifying patients at an increased risk to 
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carry a BRCA mutation. 
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Each participant was asked to evaluate a set of two statements. The first 
statement asked if he/she felt that it was one of their practice responsibilities to 
identify patients at risk of having a BRCA mutation. The majority (92.7%, n=77) of 
respondents indicated yes, 6% (n=5) indicated no, and 1.2 % (n=1) chose to not 
answer. The second statement asked if he/she felt that patient management would 
change if the patient was found to be a carrier of a BRCA mutation.  Here 87.9% 
(n=73) indicated yes, 8.4% (n=7) indicated no, and 3.6% (n=3) chose not to answer.  
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There were seven respondents that indicated that identifying patients who 
may carry a BRCA mutation was one of their practice responsibilities and in a 
subsequent question indicated that their management of a patient would not 
change if the patient carried a BRCA mutation. Conversely, five respondents that 
indicated that identifying patients who may carry a BRCA mutation was not one of 
their practice responsibilities subsequently indicated that their management of a 
patient would change if the patient carried a BRCA mutation. A wilcoxon signed-
rank test indicated that there was no significant difference between these two 
groups (z=0.5637). Additionally two respondents that indicated that identifying 
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patients who may carry a BRCA mutation was one of their practice responsibilities 
chose not to respond to the subsequent question. There was one respondent that 
chose not to answer either of the aforementioned questions.  
The next question asked respondents to identify who they feel has the 
primary responsibility of identifying patients that are at risk of carrying a mutation 
in either the BRCA1/2 gene. Respondents taking the survey online were limited to 
only one answer choice, but it was not possible to prevent those taking the paper 
version of the survey from indicating more than one response. Each of the 
following responses was not mutually exclusive. The majority of respondents 
(84.3%, n=70) indicated that Ob/Gyns should have the primary responsibility of 
identifying these patients. Primary care physicians were identified by 26.5% (n=22) 
as the second highest group believed to be responsible for identifying these 
patients. This was followed by 10.8% (n=9) of respondents choosing oncologists, 
3.6% (n=3) choosing radiologists, and 1.2% (n=1) chose other, with a written 
comment indicating that family members should have the primary role of 
identifying individuals at risk of having a BRCA mutation.  
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The final question in this section asked respondents to identify barriers they feel 
prevent the ordering of BRCA genetic testing. Multiple answers were accepted on 
both versions of the survey, indicating that the answer choices were not mutually 
exclusive. Most (80.7%, n=67) respondents indicated that the cost of testing was a 
barrier in genetic testing. Possibility of insurance discrimination was the second 
most chosen barrier by 37 respondents (44.6%). Additionally, time constraints in 
clinic (31.3%, n=26), lack of patient interest/uptake (22.9%, n=19), lack of knowledge 
regarding which patients are eligible for testing (8.4%, n=7), and feeling that BRCA 
testing is not an important aspect for their patient care (1.2%, n=1) where all 
indicated by the respondents as perceived barriers. Eight respondents (9.6%) also 
stated “other” as a potential barrier for ordering BRCA testing, and wrote in:  
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1. Physician asking questions 
2. Usually refer to genetic counseling 
3. I refer back to the PCP 
4. Insurance denial 
5. Refer to our high risk clinic for counseling rather than ordering the testing alone 
6. There are often other greater priorities at the visit 
7. Uncertain indications, understanding and interpretation of the test 
8. I have a great go to person in my multi disciplinary practice, so if risk or inquiry I 
send the patient to him 
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Part III: Utilization of BRCA testing  
All respondents answered the following series of questions by indicating 
their answer choice on a likert scale for the frequency of each situation per month. 
The answer choices were “never”, “rarely” (<1 time/month), “sometimes” (1-2 
times/month), “often” (3-4 times/month), and “on a regular basis” (≥ 5 
times/month). The first question asked how often the respondent saw a patient at 
an increased risk for HBOC. The majority (32.5%, n=27) indicated rarely, 30.1% 
(n=25) indicated sometimes, 22.9% (n=19) indicated often, 8.4% (n=7) indicated on a 
regular basis, 1.2% (n=1) indicated never, and 4.8% (n=4) chose not to respond. The 
frequency of seeing patients at an increased risk as reported in these responses and 
the number of patients seen by that physician in a typical week was not correlated 
(r=0.16). The second question asked how often the respondent received questions 
from patients about the heredity of breast cancer. The majority (39.8%, n=33) 
indicated rarely, 24.1% (n=20) indicated sometimes, 15.7% (n=13) indicated often, 
9.6% (n=8) indicated on a regular basis, 6% (n=5) indicated never, and 4.8% (n=4) 
chose not to respond. The correlation between the responses given and the number 
of patients seen in a typical week was poor (r=0.12). The third question asked how 
often the respondent received questions from patients about BRCA1/2 testing. The 
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majority (43.4%, n=36) indicated rarely, 27.7% (n=23) indicated sometimes, 9.6% 
(n=8) indicated often, 3.6% (n=3) indicated on a regular basis, 10.8% (n=9) indicated 
never, and 4.8% (n=4) chose not to respond. The fourth question asked how often 
the respondent initiated a conversation regarding genetic testing for BRCA1/2 with 
a patient. The majority (30.1%, n=25) indicated sometimes, 19.3% (n=16) indicated 
rarely, 21.7% (n=18) indicated often, 19.3% (n=16) indicated on a regular basis, 3.6% 
(n=3) indicated never, and 4.8% (n=4) chose not to respond. The fifth question asked 
how often the respondent ordered genetic testing for BRCA1/2. The majority (43.4%, 
n=36) indicated rarely, 14.4% (n=12) indicated sometimes, 6% (n=5) indicated often, 
6% (n=5) indicated on a regular basis, 22.9% (n=19) indicated never, and 7.2% (n=6) 
chose not to respond. The final question in this series asked how often the 
respondent referred a patient to a genetic counselor or other specialist in order to 
discuss genetic testing for BRCA1/2. The majority (39.8%, n=33) indicated rarely, 
21.7% (n=18) indicated sometimes, 9.6% (n=8) indicated often, 7.2% (n=6) indicated 
on a regular basis, 14.4% (n=12) indicated never, and 7.2% (n=6) chose not to 
respond.  
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Next we asked respondents to indicate what they would do after identifying 
patients at risk of carrying a BRCA1/2 mutation. Respondents could choose multiple 
answers, indicating that the answer choices were not mutually exclusive. The 
majority (53%, n=44) indicated that they would discuss HBOC and order BRCA 
testing themselves. 48.2% (n=40) of respondents indicated that they would refer the 
patient to a genetic counselor for risk assessment and possible BRCA testing. 9.6% 
(n=8) of respondents indicated that they would refer a patient to another specialist, 
including: oncologist (n=2), hematology and oncology (n=1), breast center (n=1), and 
specifically a MDAnderson Cancer Center genetic counselor (n=1). Three 
respondents did not indicate to which specialist they would refer. Additionally, one 
respondent (1.2%) indicated that they would refer the patient back to their PCP and 
another respondent (1.2%) indicated that they would do nothing, because he/she 
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did not feel that knowing whether or not a patient carries a mutation in BRCA 
would change the management of the patient.  
 
 
Part IV: Knowledge  
The first group of questions consisted of patient scenarios and respondents 
were asked whether each patient would be at an increased risk for having a 
mutation in the BRCA1 or BRCA2 gene. The first patient scenario was a patient who 
was diagnosed with breast cancer at 45 years but has no other family history of 
breast cancer. The majority of respondents, 62.7% (n= 52), correctly indicated that 
this patient would be at an increased risk, while 27.7% (n=23) indicated that this 
patient would not be at an increased risk and 9.6% (n=8) chose not to respond.  
The second patient scenario was a patient who was diagnosed with ovarian cancer 
at the age of 55 years. The majority of respondents, 53% (n= 44), correctly indicated 
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that this patient would be at an increased risk, while 36.1% (n=30) indicated that 
this patient would not be at an increased risk and 10.8% (n=9) chose not to respond. 
The third patient scenario was a patient who is Ashkenazi Jewish and was 
diagnosed with breast cancer at the age of 60 years. The majority of respondents, 
69.9% (n= 58), correctly indicated that this patient would be at an increased risk, 
while 20.5% (n=17) indicated that this patient would not be at an increased risk and 
9.6% (n=8) chose not to respond. The fourth patient scenario was a patient whose 
brother was diagnosed with breast cancer. The majority of respondents, 81.9% (n= 
68), correctly indicated that this patient would be at an increased risk, while 7.2% 
(n=6) indicated that this patient would not be at an increased risk and 10.8% (n=9) 
chose not to respond.  The fifth patient scenario was a patient whose paternal 
grandmother was diagnosed with breast cancer at the age of 50 and whose paternal 
aunt was diagnosed with breast cancer at 49 years old. The majority of respondents, 
69.9% (n= 58), correctly indicated that this patient would be at an increased risk, 
while 18.1% (n=15) indicated that this patient would not be at an increased risk and 
12% (n=10) chose not to respond. The sixth patient scenario was a patient whose 
paternal cousin was diagnosed with endometrial cancer at 45 and whose paternal 
aunt was diagnosed with colon cancer at 51 years The majority of respondents, 
48.2% (n= 40), correctly indicated that this patient would not be at an increased risk, 
while 42.2% (n=35) indicated that this patient would be at an increased risk and 
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9.6% (n=8) chose not to respond. The seventh patient scenario was a patient who 
has a family member with breast cancer, regardless of age. The majority of 
respondents, 77.1% (n=64), correctly indicated that this patient would not be at an 
increased risk, while 10.8% (n=9) indicated that this patient would be at an 
increased risk and 12% (n=10) chose not to respond. The final patient scenario was a 
patient whose mother was diagnosed with breast cancer at 60 years and whose 
maternal grandmother was diagnosed with breast cancer at the age of 70 years. The 
majority of respondents, 45.8% (n= 38), incorrectly indicated that this patient would 
be at an increased risk, while 44.6% (n=37) correctly indicated that this patient 
would not be at an increased risk and 9.6% (n=8) chose not to respond. 
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 The second group of knowledge questions consisted of a list of cancers and 
the respondents were asked to identify whether each particular cancer was 
associated with HBOC. The first cancer listed was breast cancer, which is associated 
with HBOC. The majority of respondents, 95.2% (n=79), indicated correctly that 
breast cancer is associated with HBOC while 4.8% (n=4) chose not to answer.  The 
second cancer listed was colon cancer, which is not associated with HBOC. The 
majority of respondents, 53% (n=44), incorrectly indicated that colon cancer is 
associated with HBOC while 31.3% (n=26) indicated correctly that it is not 
associated and 15.7% (n=13) chose not to answer. The third cancer, which is 
associated with HBOC, was high grade serous or endometrioid ovarian cancer. The 
majority of respondents, 78.3% (n=65), correctly indicated that that high grade 
serous or endometrioid ovarian cancer is associated with HBOC while 10.8% (n=9) 
incorrectly indicated that it is not associated, and 10.8% (n=9) chose not to answer. 
Next, participants were asked to evaluate mucinous ovarian cancer, which is not 
associated with HBOC. The majority, 42.2% (n=35), correctly indicated that 
mucinous ovarian cancer is not associated with HBOC, while 38.6% (n=32) 
indicated that this cancer is associated with HBOC, and 19.3% (n=16) chose not to 
answer. The next cancer listed was prostate cancer, which is associated with HBOC. 
The majority, 50.6% (n=42), of participants incorrectly chose that prostate cancer is 
not associated with HBOC. Only 24.1% (n=20) correctly identified prostate cancer as 
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being associated with HBOC, and 25.3% (n=21) chose not to answer. The next cancer 
listed was uterine cancer, which is not associated with HBOC. The majority, 55.4% 
(n=46), of participants correctly indicated that uterine cancer was not associated 
with HBOC, while 25.3% (n=21) of respondents incorrectly indicated that uterine 
cancer is associated with HBOC, and 25.3% (n=16) chose not to answer. The final 
cancer listed was fallopian tube cancer, which is associated with HBOC. The 
majority of respondents, 59% (n= 49), correctly identified that fallopian tube cancer 
is associated with HBOC, while 24.2% (n=20) indicated that it was not, and 7.2% 
(n=14) chose not to respond.  
The majority (86.6, n=58) of respondents that indicated that they would change 
their management of a patient if the patient carried a BRCA mutation were able to 
accurately identity ovarian cancer as being an HBOC associated cancer. However, 
nine respondents (13.4%) did not identify ovarian cancer as being an HBOC 
associated cancer. Similarly the majority (69.4%, n=43) of respondents that indicated 
that they would change their management of a patient if the patient carried a BRCA 
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mutation were able to accurately identity fallopian tube cancer as being an HBOC 
associated cancer, while 30.6% (n=19) were not.  
Respondents were asked what the lifetime risk for developing breast cancer is 
for a woman with a known BRCA mutation.  Less than half (44.6%, n=37) correctly 
identified that the lifetime risk is up to 88%. About one third of respondents (30.1%, 
n=25) indicated that the risk is up to 44%, 9.6% (n=8) indicated that the risk is up to 
22%, 1.6% (n=1) indicated that the risk is virtually 100%, 6%(n=5) indicated that they 
did not know, and 8.4% (n=7) chose not to answer. 
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Respondents were asked what the lifetime risk for developing ovarian cancer is 
for a woman with a known BRCA mutation.  About half (54.2%, n=45) correctly 
identified that the lifetime risk is up to 44%. About one fifth of respondents (19.3%, 
n=16) indicated that the risk is up to 22%, 12% (n=10) indicated that the risk is up to 
88%, 9.6% (n=8) indicated that they did not know, and 4.8% (n=4) chose not to 
answer.  
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Respondents were asked to identify the risk of inheritance for BRCA 
mutations if a known first-degree relative had an identified mutation. About half 
(48.2%, n=40) correctly identified the risk as 50%. About one third of respondents 
(28.9%, n=24) indicated the risk as 25%, and 1.6% (n=1) indicated the risk as 100%. 
There were two respondents (2.4%) that indicated that the risk level was dependent 
upon whether the maternal or paternal relative was the relative with the known 
mutation. Additionally, 14.5% (n=12) indicated that they did not know and 4.8% 
(n=4) chose not to answer. 
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Respondents were asked to identify the pattern of inheritance for BRCA 
mutations. The overwhelming majority (83.1%, n=69) correctly identified that 
mutations could be inherited from either the patients mother or father. Only 4.8% 
(n=4) indicated that a mutation could only be inherited from the patient’s mother. 
Another 6% (n=5) stated they did not know, while an additional 6% (n=5) chose not 
to respond.  
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The final knowledge question asked the respondents to identify the type of 
testing most appropriate for an Ashkenazi Jewish patient with a known familial 
mutation. Only 6% (n=5) correctly identified that multisite BRACAnalysis® would 
be the most appropriate. The majority of participants, 42.2% (n=35), stated that they 
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did not know, while 20.5% (n=17) indicated that single site BRACAnalysis® would 
be the most appropriate. Another 19.3% (n=16) indicated that comprehensive 
BRACAnalysis® would be most appropriate and 6% (n=5) stated that BART testing 
was the most appropriate for the given patient. Additionally, 6% (n=5) chose not to 
respond.  
 
 
 
 
Respondents were allowed to provide any comments with regards to this 
survey, identifying patients at risk for HBOC or BRCA testing. There were several 
respondents that opted to provide feedback, which included:  
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1. “Points out need to clarify type of BRCA analysis available and which one to 
use” 
2. “It borders on the criminal that Myriad Lab was able to patent this gene and 
to be able to charge the exorbitant amount of money they are able to get for 
this testing” 
3. “Insurance coverage is still lousy” 
4. “Should probably cover colaris testing as well” 
5. “Can we receive the answers and/or source to read” 
6. “I obviously don't know as much as I thought I did” 
 
Knowledge Score:  
An overall knowledge score was calculated for each participant. Each correct 
answer received one point value, with a maximum of 20 total points. The average 
score attained by all respondents was 11.28 (56.4%), with a range of 0-18 total 
points. The median knowledge score was calculated for each of the practice settings. 
Gynecologic oncology (n=3) was the highest scoring group with a median score of 
17(85%). Reproductive endocrinology was the next highest group (n=2) with a 
median score of 14.5(72.5%). Urogynecology (n=3) had a median of 12 (60%), 
Ob/Gyns (n=69) had a median of 11 (55%), gynecologist only (n=3) had a median 
score of 10 (50%), and MFM (n=2) had the lowest median score of 9(45%).  
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An arbitrary cut off was set at 70% for knowledge score and respondents 
were subsequently grouped into “high scorers” (above 70%) and “low scorers” 
(below 70%). The majority (69.6%, n=48) of Ob/Gyns were “low scorers”.  Again the 
high and low scorers were stratified by practice. All of the gynecology only, MFMs, 
and urogynecologists surveyed were in the “low scorers” category.  All of the 
gynecologic oncologists and reproductive endocrinologists surveyed were in the 
“high scorers” category. 
 
 
Stratification between “high and low scorers” and practice setting showed 
that 67.9% (n=38) of those in the private practice were “low scorers”. Similarly, 
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70.4% (n=19) of respondents in the academic institution practice setting were found 
to be “low scorers”.  These distributions were not statistically significant (p=0.82).  
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Both knowledge score and “high scorers” were evaluated with comparison 
to years since the completion of the respondents’ primary residency. A linear 
regression between overall knowledge score and years since completion of 
residency demonstrated a significant decrease in knowledge over time (β coefficient 
=-0.082, p=0.032).  Despite the significant trend, there was considerable variability in 
knowledge score over time since residency and these two variables were poorly 
correlated (r=-0.24). Furthermore, a logistic regression performed between “high 
scorers” and the years since respondents’ completion of primary residency, found a 
0.95 odds ratio (95% CI: -0.156 to -0.007), i.e. for every unit increase in years since 
primary residency, the odds of being a “high scorer” decrease by 5%. 
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A regression between “high scorers” and the number of patients seen was 
not statistically significant (p=0.273). About two-thirds of respondents (68.8%, n=11) 
that indicated they saw fewer than fifty patients in a typical week were found to be 
“low scorers”. 65.8% (n=23) of respondents that indicated they saw between 51-100 
patients were found to be “low scorers”. The majority (81%, n=17) of respondents 
that indicated they saw between 101-150 patients were found to be “low scorers”. 
Sixty percent (n=3) of respondents that indicated they saw between 151-200 patients 
were found to be “low scorers”, while all (100%, n=3) respondents that indicated 
they saw over two hundred patients were found to be “low scores”.  
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A linear regression between knowledge score and comfort in identifying 
patients demonstrated a non-significant decrease of 0.2% for every unit increase in 
comfort level (β coefficient = -0.20, p=0.617). High scorers and low scorers were also 
stratified by comfort.  Three quarters (75%, n=6) stated they were very 
uncomfortable and were found to be “low scorers”.  Similarly 66.67% (n=2) of 
respondents that stated they were uncomfortable and 71.4% (n=5) of respondents 
that stated they were uncertain with regards to comfort were found to be “low 
scorers”. About three quarters (70.2%, n= 33) of respondents that indicated they 
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were comfortable and 58.8% (n=10) of respondents that indicated they were very 
comfortable were found to be “low scorers”, answering less than 70% of knowledge 
based questions correctly on the survey.  
 
 
 
A chi squared test was performed between “high and low scorers” in the 
knowledge portion of the survey and reported referral to a genetic counselor. No 
statistically significant difference was found (p=0.486). About three quarters, 72.1% 
(n=31), of respondents that stated they would refer to a genetic counselor after 
identifying a patient at risk for having a BRCA mutation were “low scorers”. 
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Furthermore, 65% (n=26), of respondents that would not refer to a genetic counselor 
for further assessment and possible BRCA testing were “low scorers”.  
 
 
 
 
 
 
Similarly when evaluating “high and low scorers” by those respondents that 
would initiate a discussion and order testing themselves, 69.2% (n=27) of 
respondents that chose this option were found to be low scorers.  A chi-squared test 
was performed and found to not be significant between the two groups (p=0.918).  
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Ordering genetic testing:  
The majority (73.7%, n=14) of respondents that indicated they typically never 
order genetic testing indicated that they did not know what type of testing would 
be most appropriate for an Ashkenazi Jewish woman with a known familial 
mutation (Figure 27). One individual (5.3%) in this category indicated that they 
would order comprehensive BRACAnalysis®, two (11.8%) correctly indicated they 
would order multisite BRACAnalysis®, one (5.3%) indicated they would order 
single site BRACAnalysis®, and one (5.3%) indicated they would order 
BRACAnalysis® large rearrangement testing (BART). The majority (54.3%, n=19) of 
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participants that indicated that they rarely (<1 time/month) order genetic testing 
responded that they did not know what type of testing would be most appropriate. 
Eight individuals (22.9%) in this category indicated that they would order 
comprehensive BRACAnalysis®, six (17.1%) indicated they would order single site 
BRACAnalysis®, two (5.7%) indicated they would order BRACAnalysis® large 
rearrangement testing (BART), while no individuals chose the correct response of 
multisite BRACAnalysis®. Of the eleven respondents that indicated that they 
sometimes (1-2 times/month) order genetic testing, the majority (36.4%, n=4) of 
respondents incorrectly identified comprehensive BRACAnalysis® as the most 
appropriate testing option for the aforementioned patient. One individual (9.1%) 
correctly indicated that they would order multisite BRACAnalysis®, while three 
(27.3%) indicated single site BRACAnalysis®, one (9.1%) indicated they would order 
BRACAnalysis® large rearrangement testing (BART), and two (18.1%) respondents 
indicated that they did not know what type of testing would be most appropriate. 
Of the five respondents that indicated that they often (3-4 times/month) order 
genetic testing, the majority (80%, n=4) incorrectly identified single site 
BRACAnalysis® as the most appropriate testing option, while only one individual 
(20%) correctly indicated that they would order multisite BRACAnalysis®. No other 
testing types were chosen by respondents in this category. For those respondents 
that indicated that they order genetic testing on a regular basis (≥ 5 times/month), 
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the majority (40%, n=2) incorrectly identified single site BRACAnalysis® as the most 
appropriate testing option, while only one individual (20%) correctly indicated that 
they would order multisite BRACAnalysis®, one individual (20%) indicated they 
would order comprehensive BRACAnalysis®, and one individual (20%) indicated 
they would order BRACAnalysis® large rearrangement testing (BART). There were 
no respondents in this category that indicated that they did not know which testing 
would be most appropriate. Finally, there were three individuals that previously 
did not indicate how often they ordered testing. Of these individuals the majority 
(66.7%, n=2) indicated that they would order comprehensive BRACAnalysis®, while 
the other respondent (n=33.3%) indicated that they would order single site 
BRACAnalysis®. Of all the respondents across the categories from never ordering 
genetic testing to ordering genetic testing on a regular basis only five individuals 
correctly identified that multisite BRACAnalysis® would be the most appropriate 
test for an Ashkenazi Jewish woman with a known familial mutation (Figure 19). 
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As shown in Figure 7 above, there was a five point likert scale for which 
respondents could indicate their level of comfort in identifying patients that are at 
an increased risk of carrying a BRCA mutation. Responses between comfort and 
frequency of ordering genetic testing was further evaluated (Figure 28). Of the eight 
respondents that indicated that they were very uncomfortable with identifying 
patients at risk for carrying a BRCA mutation, the majority (75%, n=6) indicated that 
they rarely ordered genetic testing. One respondent (12.5%) indicated that they 
sometimes (1-2 times/month) order genetic testing, while another respondent 
(12.5%) indicated that they order genetic testing on a regular basis (≥ 5 
times/month).  All respondents that indicated they were uncomfortable (n=3) also 
indicated they never order genetic testing. There were seven respondents that 
indicated they felt uncertain about their level of comfort in identifying patients at 
risk for carrying a BRCA mutation. Of those respondents, the majority (42.9%, n=3) 
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indicated that they never order genetic testing, while two (28.6%) indicated that 
they rarely order genetic testing, one (14.3%) indicated that they sometimes order 
genetic testing, and one (14.3%) respondent chose not to respond. The majority of 
respondents (n=47) indicated that they were comfortable with identifying patients 
at risk for carrying a BRCA mutation. Of these respondents, eight (17%) indicated 
that they never order genetic testing, twenty four (51.1%) indicated that they rarely 
order genetic testing, six (12.8%) indicated that they sometimes order genetic 
testing, three (6.4%) indicated that they often ordered genetic testing, two (4.3%) 
indicated that they order genetic testing on a regular basis, and four (8.5%) chose 
not to respond. Finally, of respondents that indicated they were very comfortable 
(n=17) with identifying patients at risk for carrying a BRCA mutation only two 
(11.8%) indicated that they ordered genetic testing on a regular basis. Four (23.5%) 
indicated that they never ordered genetic testing, four (23.5%) indicated that they 
rarely ordered genetic testing, four (23.5%) indicated that they sometimes ordered 
genetic testing, two (11.8%) indicated that they often ordered genetic testing, and 
one (5.9%) chose not to respond.  
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DISCUSSION 
In this study, Houston area obstetricians and gynecologists were 
asked about their knowledge, attitudes, and utilization of BRCA testing in 
their practices. In 2009 the American Congress of Obstetricians and 
Gynecologists (ACOG) released a practice bulletin, which identified the 
necessity of evaluating a patient’s risk for HBOC as a routine part of obstetric 
and gynecologic practice [59]. The purpose of this study was to capture the 
current knowledge of both HBOC and BRCA testing among obstetricians and 
gynecologist in the Houston area, to assess if and how they are utilizing 
BRCA testing, and to determine what they feel their role is with regards to 
BRCA testing.  
 
Study population:  
According to the 2008 Socioeconomic Survey of ACOG Fellows our 
study is representative of the current membership with regards to gender 
and years in practice [66]. The 2008 survey found that 44.6% of members 
were female, with average years in practice of 17.59.  Furthermore, the 2008 
Socioeconomic Survey was consistent with our findings of practice setting 
indicating that 73.6% of members work in a private practice with an average 
of 6.3 physicians on site [66]. Our study found that 67.5% of respondents 
71 
 
reported working in a private practice setting with a slightly higher average 
of 9.36 physicians in their practice.  
However, in this study the majority of respondents (83%) identified 
their primary practice setting as general obstetrics and gynecology, while the 
national survey found 67.9% of the total members identifying themselves in 
this group. Similarly while our study population reported 5% to be 
gynecologists only, 4% gynecologic oncologists, 2% were maternal fetal 
medicine specialists, 2% were reproductive endocrinologists, and 4% were 
urogynecologists; the national survey reports 17.9% gynecolgists only, 1.9% 
gynecologic oncolgosits, 6.1% maternal fetal medicine specialists, 2.8% 
reproductive endocrinologists, and .9% urogynecologists [66]. In this way, it 
seems that the population surveyed was not representative of the 
subspecialties found in the national reported members of ACOG, which can 
most likely be attributed to our small sample size. 
 
Perceived role and reported comfort in identifying at risk patients:  
One of the study aims was to determine what obstetricians and 
gynecologists feel their role is in regards to BRCA testing.   An 
overwhelming 92.7% of respondents indicated that they believe that 
identifying patients at risk for HBOC is one of their practice responsibilities.  
72 
 
Furthermore, the majority (84.3%) of respondents indicated that Ob/Gyns 
have the primary responsibility of identifying patients at risk of carrying a 
BRCA mutation (Figure 9). This is supported by the majority of responses 
received when physicians were asked to indicate what they would do after 
identifying a patient at risk for carrying a BRCA mutation. Respondents 
indicated that once a patient at an increased risk of carrying a BRCA 
mutation is identified, they would typically either discuss HBOC and 
ordering BRCA testing themselves (53%) and/or refer the patient to a genetic 
counselor (48.2%).  
Our study shows that the majority (77%) of respondents felt very 
comfortable or comfortable in identifying patients who are at an increased 
risk of carrying a BRCA mutation.   A study in 2008 reported a similar level 
of comfort among 82 physicians, of which 18.3% reported gynecology as 
their area of practice. This study used a 5-point scale, with 5 being the most 
comfortable, to measure the group’s comfort when identifying potential at 
risk patients for a hereditary cancer syndrome and discussing genetic 
information. Their overall average comfort score was found to be 3.7 [67]. In 
our study a similar 5-point likert scale ranging from very uncomfortable to 
comfortable was used to assess how Ob/Gyns felt with identifying patients 
who are at an increased risk of carrying a BRCA mutation. Were we to assign 
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a 1-5 point value to each of our likert scale answer choices, giving very 
uncomfortable a 1 point value, and very comfortable a 5 point value, we 
could then calculate that our study found an overall comfort level of 3.85, 
indicating that the results seen in our study are in line with previous studies 
that evaluated comfort in identifying patients that may be at risk of carrying 
a BRCA mutation.  
 It was initially hypothesized that those that stated a higher level of 
comfort would have higher knowledge of HBOC and BRCA testing to 
support their attitude. However, this study indicates that there is no positive 
correlation between feeling comfortable identifying patients at an increased 
risk and knowledge of HBOC and BRCA testing. In comparing the 
knowledge score of each participant with regards to reported comfort in 
identifying patients at risk (Figure 24), it is seen that the difference in 
knowledge score is not statistically significantly different between 
respondents that indicated they were very uncomfortable, uncomfortable, 
uncertain, comfortable, and very comfortable. Furthermore, the majority 
(58.8%)of physicians who reported feeling very comfortable in identifying 
patients at an increased risk of carrying a BRCA mutation were found to be 
low scorers (<70% accuracy) in the knowledge portion of the survey.  
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Similarly, there was no statistical significance seen between comfort of 
identifying at risk patients and the reported frequency of ordering genetic 
testing. A quarter (25%) of respondents that stated they were very 
uncomfortable with identifying patients that may be at an increased risk for 
carrying a BRCA mutation indicated that they ordered genetic testing at least 
1-2 times per month or more. About a third (35.3%) of respondents that 
stated they were very comfortable with identifying patients that may be at an 
increased risk for carrying a BRCA mutation indicated that they ordered 
genetic testing at least 1-2 times per month or more. 
The lack of a positive correlation seen between reported comfort in 
identifying at risk patients, knowledge of HBOC/ BRCA testing, and 
frequency of ordering genetic testing is clinically significant for practicing 
physicians. These results indicate that respondents that felt very comfortable 
or comfortable in identifying patients at a high risk for carrying a mutation 
in BRCA1/2 were just as likely as those respondents that indicated they were 
very uncomfortable or uncomfortable to answer below 70% of questions 
correctly on the knowledge portion of the survey.  Furthermore, these results 
show that respondents indicate they are ordering testing even though they 
may not have the knowledge to appropriately identify patients who are truly 
at an increased risk for carrying a BRCA mutation. This raises two areas of 
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concern. First, that they are ordering testing on patients who may not truly 
be at an increased risk for carrying a mutation, thus wasting health care 
dollars and increasing patient anxiety. Secondly, due to their lack of 
knowledge, they are likely not correctly identifying patients who would 
benefit from BRCA testing, thus patients who have HBOC are likely going 
unidentified an therefore not receiving the screening/ surveillance and risk 
reductions options that could potentially prevent them from developing life 
threatening cancers. 
The US Preventive Services Task Force (USPSTF) issued a practice 
bulletin, which estimates that about 2% of women would meet the definition 
for a patient at an increased risk of carrying a BRCA mutation [58]. With the 
USPSTF bulletin in mind, we would expect that physicians that report seeing 
between 51-100 patients per week to see about 4-8 patients at risk for HBOC 
and thus carrying a mutation per month; acknowledging that this is just an 
estimate as some patients may be seen for a follow-up visit in the same week 
and thus counted twice. However, this study found that only about 10% of 
respondents indicate that they see patients who they suspect may be at an 
increased risk for HBOC on a regular basis (>5 times/month) (Figure 11). One 
possible reason for this discrepancy in the data may be that physicians are 
not in fact able to identify those patients that are at an increased risk of 
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carrying a BRCA mutation. A previous study in 2003 of 172 gynecologists 
further supports this conclusion. The 2003 study found that the majority of 
participants felt comfortable with discussing HBOC with patients that are at 
an increased risk of carrying a BRCA mutation, however, a third of 
participants also indicated some uncertainty in their basic genetic knowledge 
[63]. Furthermore, in our study, the majority of respondents (69.2%) that 
indicated that they would discuss HBOC and order BRCA testing had a 
knowledge score below 70% (Figure 26). Another previous study of 351 
primary care physicians found similar results in that there was no 
association between higher knowledge about breast cancer and having a 
discussion about risk or ordering BRCA genetic testing [68].  This study 
supports an ongoing trend of physician reported confidence in identifying 
patients at risk of carrying a BRCA mutation, without adequate knowledge 
to support such attitudes.  
 
Utilization of BRCA testing:  
About a quarter (26.4%) of respondents indicated that they order 
genetic testing at least 1-2 times per month or more.  Although the majority 
of our respondents indicated that they do not regularly see a patient at 
increased risk for HBOC, receive questions from patients about BRCA1/2 
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testing, or order BRCA testing, some report that they do (Figure 11). About 
8% of respondents reported to see a patient at increased risk for HBOC, 3.6% 
reported to receive questions about BRCA1/2 testing, and 6% report to order 
BRCA testing in a typical month.   
There was no significant correlation between the number of patients 
seen per week and the frequencies that physicians report to see patients an 
increased risk for HBOC, to receive questions from patients regarding BRCA 
testing or to actually order BRCA testing.  One would have assumed that as 
the number of patients seen in practice increased there would have been an 
increase in the number of patients that would be identified as being at an 
increased risk for HBOC, as well as an increase in the number of patients 
asking question about BRCA1/2 testing, and subsequently the frequency of 
ordering BRCA testing. The lack of correlation between these reported 
practice frequencies and patient loads points to the possibility of other 
influencing factors.  One can conclude that given the overall poor knowledge 
in regards to HBOC and BRCA testing identified through this study, 
physicians may not feel that they have patients at an increased risk and 
therefore do not order BRCA testing because they are unable to accurately 
identify such patients.  
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When comparing respondents that ordered genetic testing at least 1-2 
times per month or more with the accuracy of identifying which test would 
be the most appropriate for an Ashkenazi Jewish woman whose family has a 
known mutation in a BRCA gene, there were only three (14.3%) respondents 
who were able to correctly identify that multisite BRACAnalysis® was the 
most appropriate for the given patient. Even with a known family mutation, 
individuals of Ashkenazi Jewish ancestry should also be offered multisite 
BRACAnalysis® due to the high carrier frequency of 1/40 found in the 
Ashkenazi Jewish population. The multisite BRACAnalysis® will cover the 
three most commonly found mutations that are present in this population. 
The very low percentage of physicians who correctly answered this question 
demonstrates the need for more education about which testing is most 
appropriate based on patient presentation and risk factors. One of the 
respondents clearly echoed this conclusion with a written comment stating 
that the survey: “points out need to clarify type of BRCA analysis available 
and which one to use.”  
Another goal of this study was to understand what a physician would 
do once he/she identified a patient that was at an increased risk of being a 
BRCA carrier. The majority of respondents (53%) indicated that they would 
discuss HBOC and order BRCA genetic testing themselves (Figure 12). 
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However, as previously discussed, the majority of respondents in our study 
also indicated that they rarely (<1 time per month) order genetic testing 
(Figure 11). 
 While most (80.7%) respondents indicated that the cost of testing a 
greatest barrier that prevented them from ordering BRCA genetic testing, just 
under half (44.6%) felt that the possibility of insurance discrimination was 
another barrier preventing them from ordering this testing (Figure 10). 
Brandt et al (2008) found that about a third of their respondents also cited 
insurance discrimination as a barrier in ordering genetic testing.  In 2008, the 
Genetic Information Nondiscrimination Act (GINA) was passed, which 
protects all individuals and their families from being discriminated, both in 
the workplace and by medical insurance companies, based on genetic 
information. Education and awareness of GINA, therefore, could ultimately 
eliminate this perceived barrier. 
Just under half (48.2%) of physicians surveyed in this study indicated 
that they would refer a patient with an increased risk of carrying a BRCA 
mutation to a genetic counselor. Two previous studies found similar 
incidences of referral to genetic counselors. A 2003 study of 172 German 
gynecologists found that 58% of gynecologists surveyed recommended 
genetic counseling to their patients, while only 34% had referred their 
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patients to a genetic counselor within the past twelve months[63].  Another 
study found that of the 214 physicians surveyed, 51% had referred to a 
genetic counselor after identifying a patient at risk for HBOC [69].  Referring 
to a genetic counselor was also further evaluated with relation to knowledge. 
In our study, the majority of respondents (72.1%) that indicated that they 
would refer to a genetic counselor had a knowledge score below 70% (Figure 
25). It can be concluded that respondents that would refer to a genetic 
counselor may see the benefits of utilizing a cancer genetic counselor that can 
assist with discussing hereditary cancer and facilitate genetic testing. 
However, identifying which patients may be at an increased risk of carrying 
a BRCA mutation and therefore benefit from a referral to a genetic counselor 
is the first step in order to utilize this service. 
 
 
 
Knowledge regarding HBOC and BRCA testing  
Our study shows that the overall knowledge of Ob/Gyns surveyed is 
poor. An overall knowledge score was calculated for each participant. Out of 
a total of twenty possible points, the mean for all respondents (n=83) was 
11.28 with a range of 0-18 points. This point value corresponds to a mean 
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accuracy rate of 56.4%. No respondents answered all of the knowledge 
questions correctly. Not surprisingly, the highest scoring group was the 
gynecologic oncologists as one would assume they regularly see ovarian 
cancer patients in their practices. A similar European study, which evaluated 
243 primary care physicians’ knowledge of HBOC via survey, found that the 
Ob/Gyns in their study population had a lower average knowledge score of 
38.6%. Oncologists in this same population were shown to have the highest 
knowledge with regards to HBOC with an average 68.6% accuracy rate, 
which is consistent with our study findings [70]. 
Knowledge regarding cancers that are associated with HBOC was 
generally good across this study, with one notable exception. Respondents 
could accurately indicate that both breast and ovarian cancers are associated 
with HBOC, with 95.2% and 78.3% accuracy, respectively.  However, only 
24.1% of respondents could correctly identify that prostate cancer is 
associated with HBOC. The risks of developing prostate cancer for males 
who carry a BRCA mutation, specifically a BRCA2 mutation, can be as high 
as 20%. Typically these cancers will be diagnosed at a younger age than in 
the general population. Increased awareness of the association of prostate 
cancer with HBOC is another area where education is needed. Another area 
suggesting the need for increased education was highlighted when 
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evaluating the respondent’s knowledge of the lifetime risks for developing 
both breast and ovarian cancers for a woman with a know BRCA mutation. 
About half of respondents could accurately indicate that a woman’s chance 
for breast cancer may be as high as 88% and her chance for ovarian cancer 
may be as high as 44% if she were a carrier of a BRCA mutation. While, about 
40% of respondents underestimated a woman’s risk for developing breast 
cancer and about 20% underestimated a woman’s risk for developing 
ovarian cancer if she were a carrier of a BRCA mutation.   
A statistically significant difference was found between the 
knowledge score and the years since completion of the respondent’s primary 
residency.  Our data identified a decrease of approximately one point in the 
overall knowledge score for every ten years since the completion of 
residency.  A study in 2010, which examined 157 Ob/Gyn resident’s 
knowledge of HBOC and Lynch Syndrome, found that their knowledge was 
slightly increased as compared to that which was found in our survey [71]. 
In this 2010 study, 51% of residents could accurately identify the autosomal 
dominant pattern of inheritance of HBOC, 97% correctly identified ovarian 
cancer as a being associated with HBOC, and 51% incorrectly identified that 
colon cancer is associated with HBOC. Our study shows slightly decreased 
knowledge in that: 49% of respondents could identify the autosomal 
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dominant mode of inheritance of HBOC, 78.3% correctly identified ovarian 
cancer as a being associated with HBOC, and 53% incorrectly identified that 
colon cancer is associated with HBOC. According to our study those 
individuals still in residency should have a slightly increased knowledge 
score. Another study in 2000, which surveyed 564 ACOG fellows, further 
supports this conclusion. This study found that younger physicians were 
more likely to accurately answer questions in the knowledge portion of the 
survey, which focused on both hereditary cancers and general genetic 
information [72].   
One possible argument could be made that residents score higher as 
compared to board eligible/certified Ob/Gyns because of the residents’ 
connection with an academic setting.  However, no significance was found in 
our study to support this conclusion. When the knowledge score in this 
study was arbitrarily stratified as “high scorers” (above 70% correct) and 
“low scorers” (below 70% correct) it was seen that the there was no 
significance between the primary practice setting and knowledge. In this 
way it appears that those respondents that practiced at an academic 
institution did not show an added benefit that may have otherwise been 
presumed based on the connection with an academic institution, in 
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comparison to those that indicated they primarily practiced in a private 
practice.  
 
Strengths and Limitations:  
Since the ACOG practice bulletin in 2009, there have been no studies, 
to our knowledge, that have addressed whether or not OB/ Gyns are in 
agreement with these practice guidelines and how well they are adhering to 
them. This study seems to be the first study that has focused on the attitudes, 
utilizations, and knowledge of HBOC and BRCA in US Ob/Gyns. Through 
the knowledge portion of the survey, we were able to identify areas that 
need further attention for universal benefit for both physicians and patients. 
These areas include both identifying patients that may be at an increased risk 
for HBOC and identifying cancers that are associated with HBOC. This study 
also captured the attitudes of physicians with regards to their role in 
identifying patients and in barriers that may prevent them from ordering 
BRCA genetic testing. Indicating that the majority of patients feel 
comfortable with identifying patients that may be at an increased risk of 
carrying a BRCA mutation and that perceived barriers to BRCA genetic 
testing include the cost of testing and the fear of insurance discrimination.  
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 While our sample of Ob/Gyns reached across various hospital systems 
in the Houston area, the overall sample size was small (n=83).  Due to the 
small sample size, there was not an adequate amount of respondents that fell 
into each subspecialty. In this way the study was limited in terms of the 
ability for further stratification and analysis by specialty. While this study’s 
population is representative of the greater Houston area, one may not be able 
to generalize these results to other areas of the country.  Furthermore, all of 
the factors measured in this study were based on the self-reporting of our 
respondents, and may not accurately reflect true practice behaviors. Another 
possible limitation is the presence of selection bias that may have resulted 
due to the voluntary and thus self-selection of the study sample from our 
target population.  It is possible that the physicians who responded and are 
part of our study sample may have a heightened interest in HBOC. If this 
were the case, then the findings reported in this study may be skewed 
towards those physicians who feel that identifying at risk patients is 
important, those that may utilize testing more often, and those that may have 
a higher amount of knowledge than their peers who chose not to complete 
our survey.  It is quite possible that results would actually be less favorable 
in an unbiased sample. Another limitation of this study is that two formats of 
the survey that were distributed. While some questions clearly stated to 
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choose only one answer, some participants with hard copy versions of the 
survey chose more than one answer. Moreover, participants with the hard 
copy version were free to go back to previous questions to change their 
answers or write in answers.  The online version prevented participants from 
going back to previously answered questions and allowed limited areas for 
write in answers.  Finally, the survey distributed was not a validated survey, 
as it was created specifically for this study.  
 
Final Conclusions and Future Studies: 
This study shows that the majority of Ob/Gyns feel that it is their role 
to identify patients that may be at an increased risk of having a BRCA 
mutation. Overall, reported comfort in identifying patients that may be at 
and increased risk of having a BRCA mutation is high. Most Ob/Gyns would 
agree that they are comfortable or very comfortable with this task.  
Furthermore, most Ob/Gyns report that they would discuss HBOC and order 
BRCA testing themselves once they have identified patients that may be at an 
increased risk. However, only about a quarter of participants indicated that 
they order BRCA genetic testing one to two times per month, or more.  
Finally, this study demonstrates that the overall knowledge of HBOC and 
BRCA testing is poor. Thus, this study points out the need for more 
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education regarding HBOC, molecular BRCA testing, and strategies for 
identifying patients that may be at risk for having a mutation in a BRCA 
gene. Furthermore, it emphasizes the importance of raising awareness to 
current practice guidelines and recommendations that can assist 
obstetricians and gynecologist to better identify and manage patients that 
may be at an increased risk of having HBOC, which could have otherwise 
been overlooked.  
 Future directions of this study are to replicate the study across a larger 
population of Ob/ Gyns to capture the attitudes, utilization, and knowledge 
across a more diverse population.  An education module with pre and post 
testing could also be implemented to capture the significance of education 
about HBOC and BRCA testing. Furthermore, another study to examine how 
physicians are identifying patients that are at an increased risk may help 
explain the reported level of comfort in identifying patients at an increased 
risk of having a BRCA mutation that was seen in this study.  Another 
direction that could be taken is to adapt the survey questions created here to 
analyze other physician’s knowledge about different hereditary cancers or 
genetic conditions. Results of a survey like this could prove beneficial in 
demonstrating the need for more genetics training, with the ultimate goal of 
providing better patient care.  
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APPENDIX A 
Part I.  
1. What is your gender? 
 Male 
 Female 
 
2. How many years has it been since the completion of your primary residency?  
 
_______________ 
 
3. Are you board certified in Obstetrics and Gynecolgoy? 
 Yes 
 No 
 
4. Are you boarded in any sub-specialty? 
 No 
 Yes, please indicate which one(s) below: 
i. Gynecologic Oncology 
ii. Maternal Fetal Medicine 
iii. Reproductive Endocrinology 
iv. Urogynecology 
v. Other: _____________ 
 
5. Which of the following best describes your area of practice? 
 General Obstetrics and Gynecology 
 Gynecology only 
 Obstetrics only 
 Gynecologic oncology 
 Maternal fetal medicine 
 Reproductive endocrinology 
 Urogynecology 
 Other _________ 
 
6. What is your primary practice setting? Choose all that apply. 
 Private Practice- please indicate the number of Ob/Gyns in your group _______ 
 Academic Institution/University Medical Center  
 Other ______________ 
 
7. On average, how many patients do you see in the outpatient setting per week? 
 <50 
 51-100 
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 101-150 
 151-200 
 >200 
 
 
 
Part II.  
 
1. How comfortable do you feel identifying patients who are at an increased risk of carrying a 
BRCA mutation?  
 
                             
Very Uncomfortable      Uncomfortable      Uncertain      Comfortable      Very Comfortable 
 
 
2. Please indicate your answer choice by marking the appropriate column below:  
 Yes No 
That it is one of your practice responsibilities to identify patients who 
may carry a mutation in BRCA1/2? 
  
That your management of a patient would change if you knew she 
carried a mutation in BRCA1/2?  
  
 
3. Who do you feel has the primary responsibility of identifying patients who may be at an 
increased risk of carrying a mutation in BRCA1/2? 
 Obstetrician/ Gynecologist 
 General Practitioner/ Primary Care Physician 
 Radiologist 
 Oncologist 
 Other_____________________ 
 
4. What barriers do you feel prevent you from ordering genetic testing of the BRCA genes? 
Chose all that apply.   
 Cost of the testing 
 The possibility of insurance discrimination if patient is found to be a carrier 
 Lack of patient interest/ uptake 
 Time constraints in my clinic  
 Lack of knowledge regarding which patients are eligible for testing 
 I do not feel that I have any patients who are at an increased risk of having a BRCA 
mutation 
 I do not feel that it is relevant/ important to the care of my patients 
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 Other _____________ 
 
 
 
 
 
 
Part III. 
1. Please indicate you answer choice by marking the appropriate column below:  
 
2. If you identify a patient who you believe is at risk for carrying a mutation in BRCA1/2, what 
would you do? 
 Discuss hereditary breast and ovarian cancer and order the testing yourself 
 Refer the patient to their primary care physician for testing 
 Refer the patient to a genetic counselor for risk assessment and possible testing  
On average, how many times each 
month do you… 
Neve
r 
Rarely 
(<1 
time/mo) 
 
Sometime
s 
(1-2 
times/mo) 
Often 
(3-4 
times/mo) 
 
On a 
regular 
basis  
(≥5 
times/mo) 
 
See a patient that you suspect has an 
increased risk for HBOC? 
     
Receive questions from patients about 
the heredity of breast cancer? 
     
Receive questions from patients about 
BRCA1/2 testing? 
     
Initiate a conversation regarding 
genetic testing for BRCA1/2 with your 
patients? 
     
Order genetic testing for BRCA1/2?      
Refer a patient to a genetic counselor, 
or other specialist, in order to discuss 
genetic testing for BRCA1/2? 
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 Refer the patient to another specialist. Please specify which type of specialist:  
_____________ 
 Nothing, because you do not feel that it would change your management of the 
patient 
 Other _______________ 
 
 
 
 
 
 
 
 
 
 
Part IV.  
 
 
 
 1-2. Please indicate your answer choice by marking the appropriate column below:  
 
1. Which of the following patients would you consider at an increased risk for 
having a mutation in BRCA1 or BRCA2? 
Yes No 
A patient who was diagnosed with breast cancer at 45 years but has no other family 
history of breast cancer? 
  
A patient whose mother was diagnosed with breast cancer at 60 years and whose 
maternal grandmother was diagnosed with breast cancer at the age of 70 years? 
  
A patient who was diagnosed with ovarian cancer at the age of 55 years?   
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3. What is the lifetime risk for developing breast cancer for a woman who has a known BRCA 
mutation? 
 Up to 22% 
 Up to 44% 
 Up to 88% 
 Virtually 100% 
 I do not know 
 
4. What is the lifetime risk for 
developing ovarian cancer for a woman who has a known BRCA mutation? 
 Up to 22% 
 Up to 44% 
 Up to 88% 
 Virtually 100% 
A patient who is Ashkenazi Jewish and was diagnosed with breast cancer at the age 
of 60 years? 
  
A patient whose brother was diagnosed with breast cancer?   
A patient whose paternal grandmother was diagnosed with breast cancer at the age 
of 50 and whose paternal aunt was diagnosed with breast cancer at 49 years old? 
  
A patient whose paternal cousin was diagnosed with endometrial cancer at 45 and 
whose paternal aunt was diagnosed with colon cancer at 51? 
  
A patient who has a family member with breast cancer, regardless of age.    
2. Which of the following cancers are associated with BRCA mutations? Yes No 
Breast cancer   
Colon cancer   
High grade serous or endometrioid ovarian cancer   
Mucinous ovarian cancer   
Prostate cancer   
Uterine cancer   
Fallopian tube cancer   
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 I do not know 
 
5. What is the chance of a woman having a mutation in BRCA1/2 if she has a first degree 
relative with a known BRCA mutation? 
 0% 
 25% 
 50% 
 100%  
 This is dependent upon whether it is a maternal or paternal relative 
 I do not know 
 
6. A woman can inherit a mutation in BRCA1/2: 
 From her mother only 
 From her father only 
 From either her mother or her father 
 These mutations are not typically inherited, it is most likely that the mutation 
started in the affected individual 
 I do not know 
 
7. What testing would you order for an Ashkenazi Jewish patient with a known familial 
mutation in BRCA1/2? 
 Comprehensive BRAC Analysis 
 Multisite BRAC Analysis 
 Single Site BRAC Analysis 
 BRAC Analysis Large Rearrangement Testing (BART) 
 I do not know  
 
 
Please provide us with any comments regarding this survey, identifying patients at risk for 
hereditary breast and ovarian cancer (HBOC) or BRCA testing:  
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_______________ 
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APPENDIX B 
Research study (Survey) Regarding Obstetricians and Gynecologists knowledge, attitudes toward, and 
utilization of BRCA testing 
 
You are invited to take part in a research project called, “Knowledge, attitudes toward, and utilization of 
BRCA testing,” conducted by Salma Nassef, of the University of Texas Health Science Center. For this 
research project, she will be called the Principal Investigator or PI. 
 
The purpose of this research study is to assess obstetricians and gynecologists’ medical background, 
experience, and opinions regarding the utilization of BRCA testing for their patient population. This 
study is composed of multiple-choice questions, which we hope will allow us to better understand current 
practice regarding this topic. Space is available for additional comments should you find this necessary. 
There are no other alternative ways to participate in this study without filling out the survey below. There 
are no known risks for your participation in this study. 
 
Completion of this anonymous survey is voluntary and for research purposes only. It should take less 
than 15 minutes to complete this survey. All responses are completely confidential, and you will not be 
personally identified in any reports or publications of this study. Data will be summarized and presented 
as part of a thesis project at The University of Texas Graduate School of Biomedical Sciences at Houston. 
By completing and submitting the questionnaire, you are implying consent to have your answers used 
and shared among collaborators for this study. There is no financial compensation for taking this survey. 
 
Although the results of this study will be useful for doctors and other health professionals, there may be 
no direct benefit to you for participating in this study. You can refuse to answer or skip any questions or 
stop taking the survey at any time. Refusing to take part or stopping at any point during the survey will 
involve no penalty. If you decide to participate in the study, it is very important that you answer the 
questions as honestly as you can. 
 
If you have any questions or concerns, please contact Salma Nassef or Cathy Sullivan, MS, CGC at 713-
500-6381. Thank you very much for your input regarding this important issue. 
 
Sincerely, 
 
Salma Nassef  
Genetic Counseling Student  
UT Health Science Center at Houston  
Graduate School of Biomedical Sciences  
Principal Investigator 
 
Cathy M. Sullivan, MS, CGC  
Genetic Counselor/Clinical Instructor  
UT Health Science Center at Houston  
Department of Obstetrics, Gynecology and Reproductive Sciences  
Committee Chair 
 
Manju Monga, MD  
Senior Faculty 
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Maternal Fetal Medicine  
Department of Obstetrics and Gynecology  
Baylor College of Medicine 
Committee Member 
 
Jon Gogola, MD  
Chief of Staff Memorial Hermann Memorial City  
Greater Houston Obstetrics and Gynecology 
Associates, LLP  
Committee Member 
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